GENinCode Plc (AIM:GENI)

Market Cap	6.40M +43.9%
Revenue (ttm)	3.08M +13.9%
Net Income	-5.71M
EPS	-0.02
Shares Out	753.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,186,313
Open	0.9640
Previous Close	0.9500
Day's Range	0.8125 - 0.9700
52-Week Range	0.7500 - 5.5000
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 24, 2026

About GENinCode

GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient’s health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of familial hypercholesterolemia with further coronary risk stratification of the patient; and SUDD inCode, a genetic diagnostic test for familial heart dis...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2018
• Employees: 44
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: GENI

Financial Performance

In 2025, GENinCode's revenue was 3.08 million, an increase of 13.88% compared to the previous year's 2.70 million. Losses were -5.71 million, 28.7% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error